Bridger Management LLC Increased Alexion Pharmaceuticals INC (ALXN) Stake by $48.88 Million

March 14, 2018 - By Vivian Park

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It dived, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Thornburg Investment Management reported 0.1% stake. Fred Alger Mngmt Incorporated owns 90,097 shares. Franklin Resources reported 2.34 million shares. Da Davidson Communications holds 2,156 shares. Mason Street Advisors Ltd reported 30,982 shares stake. Ledyard Bancshares holds 0.01% or 419 shares. Winslow Evans & Crocker Inc has 0.02% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 404 shares. Louisiana State Employees Retirement System, Louisiana-based fund reported 13,900 shares. Opus Point Prtnrs Mgmt Limited Com holds 11,447 shares or 1.44% of its portfolio. Management Of Virginia Ltd Liability Corp stated it has 4,760 shares or 0.16% of all its holdings. Panagora Asset Mngmt reported 14,987 shares or 0.01% of all its holdings. State Of Wisconsin Invest Board owns 247,254 shares. Moreover, Dsm Cap Ptnrs Limited Com has 2.8% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 1.41 million shares. Serv Automobile Association owns 0.05% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 118,340 shares. Andra Ap accumulated 9,000 shares.

Since October 2, 2017, it had 0 insider purchases, and 13 sales for $4.63 million activity. The insider O’Neill Julie sold 1,625 shares worth $194,723. 2,553 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares with value of $310,521 were sold by HANTSON LUDWIG. Shares for $76,805 were sold by Wagner Heidi L. Goff Brian had sold 1,651 shares worth $192,028 on Tuesday, February 6. Shares for $707,048 were sold by Clancy Paul J. Franchini Indrani Lall had sold 1,459 shares worth $169,696 on Tuesday, February 6.

Roberto Mignone increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 169.47% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc bought 349,114 shares as the company’s stock declined 11.63% while stock markets rallied. The hedge fund run by Roberto Mignone held 555,120 shares of the health care company at the end of 2017Q3, valued at $77.88 million, up from 206,006 at the end of the previous reported quarter. Bridger Management Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $27.20 billion market cap company. The stock increased 1.32% or $1.6 during the last trading session, reaching $122.68. About 1.20M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since March 14, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Bridger Management Llc, which manages about $3.11B and $1.67B US Long portfolio, decreased its stake in Impax Laboratories Inc (NASDAQ:IPXL) by 738,687 shares to 602,456 shares, valued at $12.23 million in 2017Q3, according to the filing. It also reduced its holding in Tempur Sealy Intl Inc (NYSE:TPX) by 191,206 shares in the quarter, leaving it with 1.04M shares, and cut its stake in Nektar Therapeutics (NASDAQ:NKTR).

More news for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were recently published by:, which released: “Alexion Pharmaceuticals (ALXN) Shares Cross Above 200 DMA” on March 09, 2018.‘s article titled: “Alexion Ups Its Game With ALXN1210 SC” and published on February 20, 2018 is yet another important article.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was upgraded by Goldman Sachs on Friday, October 28 to “Buy”. Wedbush initiated the stock with “Neutral” rating in Friday, September 23 report. The firm has “Hold” rating given on Thursday, July 27 by Jefferies. The firm has “Buy” rating by UBS given on Thursday, February 4. The company was maintained on Friday, February 9 by Deutsche Bank. Barclays Capital maintained the stock with “Equal-Weight” rating in Thursday, February 4 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Morgan Stanley on Friday, July 28. The rating was upgraded by JP Morgan on Tuesday, September 5 to “Overweight”. The rating was maintained by Piper Jaffray on Thursday, February 8 with “Buy”. Suntrust Robinson initiated the stock with “Buy” rating in Thursday, January 7 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.